253 related articles for article (PubMed ID: 17129632)
1. Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-Dox-AGM in breast cancer cells.
Greco F; Vicent MJ; Gee S; Jones AT; Gee J; Nicholson RI; Duncan R
J Control Release; 2007 Jan; 117(1):28-39. PubMed ID: 17129632
[TBL] [Abstract][Full Text] [Related]
2. HPMA copolymer-aminoglutethimide conjugates inhibit aromatase in MCF-7 cell lines.
Greco F; Vicent MJ; Penning NA; Nicholson RI; Duncan R
J Drug Target; 2005; 13(8-9):459-70. PubMed ID: 16332571
[TBL] [Abstract][Full Text] [Related]
3. Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck.
Nan A; Ghandehari H; Hebert C; Siavash H; Nikitakis N; Reynolds M; Sauk JJ
J Drug Target; 2005 Apr; 13(3):189-97. PubMed ID: 16036307
[TBL] [Abstract][Full Text] [Related]
4. PDEPT: polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as a model combination.
Satchi-Fainaro R; Hailu H; Davies JW; Summerford C; Duncan R
Bioconjug Chem; 2003; 14(4):797-804. PubMed ID: 12862433
[TBL] [Abstract][Full Text] [Related]
5. Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect.
Kovár M; Strohalm J; Etrych T; Ulbrich K; Ríhová B
Bioconjug Chem; 2002; 13(2):206-15. PubMed ID: 11906257
[TBL] [Abstract][Full Text] [Related]
6. Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates.
Luo Y; Bernshaw NJ; Lu ZR; Kopecek J; Prestwich GD
Pharm Res; 2002 Apr; 19(4):396-402. PubMed ID: 12033370
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin-loaded, charge reversible, folate modified HPMA copolymer conjugates for active cancer cell targeting.
Li L; Yang Q; Zhou Z; Zhong J; Huang Y
Biomaterials; 2014 Jun; 35(19):5171-87. PubMed ID: 24702960
[TBL] [Abstract][Full Text] [Related]
8. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.
Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H
Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin release is not a prerequisite for the in vitro cytotoxicity of HPMA-based pharmaceuticals: in vitro effect of extra drug-free GlyPheLeuGly sequences.
Ríhová B; Strohalm J; Hovorka O; Subr V; Etrych T; Chytil P; Pola R; Plocová D; Boucek J; Ulbrich K
J Control Release; 2008 Apr; 127(2):110-20. PubMed ID: 18325618
[TBL] [Abstract][Full Text] [Related]
10. HPMA copolymer-bound doxorubicin induces apoptosis in ovarian carcinoma cells by the disruption of mitochondrial function.
Malugin A; Kopecková P; Kopecek J
Mol Pharm; 2006; 3(3):351-61. PubMed ID: 16749867
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral Distribution and pH-Dependent Drug Release of High Molecular Weight HPMA Copolymer Drug Conjugates Strongly Depend on Specific Tumor Substructure and Microenvironment.
Noack AK; Lucas H; Chytil P; Etrych T; Mäder K; Mueller T
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825790
[TBL] [Abstract][Full Text] [Related]
12. Polymer conjugates of doxorubicin bound through an amide and hydrazone bond: Impact of the carrier structure onto synergistic action in the treatment of solid tumours.
Etrych T; Subr V; Laga R; Ríhová B; Ulbrich K
Eur J Pharm Sci; 2014 Jul; 58():1-12. PubMed ID: 24632485
[TBL] [Abstract][Full Text] [Related]
13. HPMA copolymer-1,5-diazaanthraquinone conjugates as novel anticancer therapeutics.
Vicent MJ; Manzanaro S; de la Fuente JA; Duncan R
J Drug Target; 2004; 12(8):503-15. PubMed ID: 15621676
[TBL] [Abstract][Full Text] [Related]
14. Biodegradable and amphiphilic block copolymer-doxorubicin conjugate as polymeric nanoscale drug delivery vehicle for breast cancer therapy.
Yang Y; Pan D; Luo K; Li L; Gu Z
Biomaterials; 2013 Nov; 34(33):8430-43. PubMed ID: 23896006
[TBL] [Abstract][Full Text] [Related]
15. The structure of polymer carriers controls the efficacy of the experimental combination treatment of tumors with HPMA copolymer conjugates carrying doxorubicin and docetaxel.
Šírová M; Strohalm J; Chytil P; Lidický O; Tomala J; Říhová B; Etrych T
J Control Release; 2017 Jan; 246():1-11. PubMed ID: 27940304
[TBL] [Abstract][Full Text] [Related]
16. Overcoming multidrug resistance in Dox-resistant neuroblastoma cell lines via treatment with HPMA copolymer conjugates containing anthracyclines and P-gp inhibitors.
Koziolová E; Janoušková O; Cuchalová L; Hvězdová Z; Hraběta J; Eckschlager T; Sivák L; Ulbrich K; Etrych T; Šubr V
J Control Release; 2016 Jul; 233():136-46. PubMed ID: 27189135
[TBL] [Abstract][Full Text] [Related]
17. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro.
Omelyanenko V; Gentry C; Kopecková P; Kopecek J
Int J Cancer; 1998 Feb; 75(4):600-8. PubMed ID: 9466663
[TBL] [Abstract][Full Text] [Related]
18. Cooperativity between free and N-(2-hydroxypropyl) methacrylamide copolymer bound adriamycin and meso-chlorin e6 monoethylene diamine induced photodynamic therapy in human epithelial ovarian carcinoma in vitro.
Lu JM; Peterson CM; Guo-Shiah J; Gu ZW; Peterson CA; Straight RC; Kopecek J
Int J Oncol; 1999 Jul; 15(1):5-16. PubMed ID: 10375588
[TBL] [Abstract][Full Text] [Related]
19. Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells.
David A; Kopecková P; Minko T; Rubinstein A; Kopecek J
Eur J Cancer; 2004 Jan; 40(1):148-57. PubMed ID: 14687799
[TBL] [Abstract][Full Text] [Related]
20. Polyacetal-doxorubicin conjugates designed for pH-dependent degradation.
Tomlinson R; Heller J; Brocchini S; Duncan R
Bioconjug Chem; 2003; 14(6):1096-106. PubMed ID: 14624622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
